Stacy Remiszewski
Research Subjects
Stacy Remiszewski has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Lillian W. Chiang
Evrys Bio, LLC, Pennsylvania Biotechnology Center, Doylestown, PA, 18902, USA
2 shared publications - Adrian J. Fretland
10Repare Therapeutics, Cambridge, Massachusetts
1 shared publication - Andrew F. Donnell
Bristol Myers Squibb, 3551 Lawrenceville Rd, Lawrence Township, New Jersey 08648, United States
1 shared publication Andrew Snedeker
Baruch S. Blumberg Institute, Doylestown, PA, 18902, USA
1 shared publicationAnn Polonskaia
Departments of Discovery Chemistry, ‡Discovery Technologies, §Non-clinical Safety, Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
1 shared publicationAnthony Specian
Departments of Discovery Chemistry, ‡Discovery Technologies, §Non-clinical Safety, Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
1 shared publication
Latest Publications
- Open Access
- 22 May 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (7) , 110274
Structural basis for sirtuin 2 activity and modulation: Current state and opportunities
- 22 May 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (7) , 110274
Open AccessStructural basis for sirtuin 2 activity and modulation: Current state and opportunities
- 18 April 2024
- Published by Elsevier in Antiviral Research
- Vol. 226, 105888
An allosteric inhibitor of sirtuin 2 blocks hepatitis B virus covalently closed circular DNA establishment and its transcriptional activity
- 18 April 2024
- Published by Elsevier in Antiviral Research
- Vol. 226, 105888
An allosteric inhibitor of sirtuin 2 blocks hepatitis B virus covalently closed circular DNA establishment and its transcriptional activity
- 9 August 2023
- Published by Elsevier in Antiviral Research
- Vol. 217, 105698
Inhibition of SIRT2 promotes death of human cytomegalovirus-infected peripheral blood monocytes via apoptosis and necroptosis
- 9 August 2023
- Published by Elsevier in Antiviral Research
- Vol. 217, 105698
Inhibition of SIRT2 promotes death of human cytomegalovirus-infected peripheral blood monocytes via apoptosis and necroptosis
- 1 October 2013
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 56 (20) , 7772-7787
Benzazepinones and Benzoxazepinones as Antagonists of Inhibitor of Apoptosis Proteins (IAPs) Selective for the Second Baculovirus IAP Repeat (BIR2) Domain
XIAP is a key regulator of apoptosis, and its overexpression in cancer cells may contribute to their survival. The antiapoptotic function of XIAP derives from its BIR domains, which bind to and inhibit pro-apoptotic caspases. Most known IAP inhibitors are selective for the BIR3 domain and bind to cIAP1 and cIAP2 as well as XIAP. Pathways activated upon cIAP binding contribute to the function of these compounds. Inhibitors selective for XIAP should exert pro-apoptotic effects through competition with the terminal caspases. This paper details our synthetic explorations of a novel XIAP BIR2-selective benzazepinone screening hit with a focus on increasing BIR2 potency and overcoming high in vivo clearance. These efforts led to the discovery of benzoxazepinone 40, a potent BIR2-selective inhibitor with good in vivo pharmacokinetic properties which potentiates apoptotic signaling in a manner mechanistically distinct from that of known pan-IAP inhibitors.
- 1 October 2013
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 56 (20) , 7772-7787
Benzazepinones and Benzoxazepinones as Antagonists of Inhibitor of Apoptosis Proteins (IAPs) Selective for the Second Baculovirus IAP Repeat (BIR2) Domain
XIAP is a key regulator of apoptosis, and its overexpression in cancer cells may contribute to their survival. The antiapoptotic function of XIAP derives from its BIR domains, which bind to and inhibit pro-apoptotic caspases. Most known IAP inhibitors are selective for the BIR3 domain and bind to cIAP1 and cIAP2 as well as XIAP. Pathways activated upon cIAP binding contribute to the function of these compounds. Inhibitors selective for XIAP should exert pro-apoptotic effects through competition with the terminal caspases. This paper details our synthetic explorations of a novel XIAP BIR2-selective benzazepinone screening hit with a focus on increasing BIR2 potency and overcoming high in vivo clearance. These efforts led to the discovery of benzoxazepinone 40, a potent BIR2-selective inhibitor with good in vivo pharmacokinetic properties which potentiates apoptotic signaling in a manner mechanistically distinct from that of known pan-IAP inhibitors.